文献速递乳腺癌

转移性乳腺癌中的免疫治疗与靶向治疗联合应用

Immunotherapy and targeted therapy combinations in metastatic breast cancer.
PubMed 文献 · Lancet Oncol · 2019-01-01

本文为个人观点文章,综述转移性乳腺癌中免疫治疗与分子靶向治疗联合方案的安全性和疗效数据及正在进行的探索,涵盖与HER2靶向治疗、CDK4/6抑制剂、血管生成抑制剂、PARP抑制剂以及化疗和放疗的联合。

要点

  • 抗PD-1和抗PD-L1单药在转移性乳腺癌中疗效有限,部分因多数乳腺癌肿瘤浸润淋巴细胞少。
  • 免疫治疗与分子靶向治疗联合是转移性乳腺癌的研究方向。
  • 综述覆盖与HER2靶向、CDK4/6抑制剂、血管生成抑制剂、PARP抑制剂及化疗放疗的联合。

核心结论

  • 免疫治疗正成为乳腺癌新的治疗手段,免疫治疗与分子靶向治疗联合用于转移性乳腺癌的研究兴趣日益增长。

研究设计与样本

  • 本文为个人观点(Personal View)文章,综述现有数据及正在进行的评估免疫治疗联合方案安全性和疗效的工作。

主要发现

  • 抗PD-1和抗PD-L1单克隆抗体单药治疗在转移性乳腺癌患者中显示疗效有限,部分原因在于多数乳腺癌中肿瘤浸润淋巴细胞数量少。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunotherapy is emerging as a new treatment modality in breast cancer. After long-standing use of endocrine therapy and targeted biological therapy, improved understanding of immune evasion by cancer cells and the discovery of selective immune checkpoint inhibitors have created novel opportunities for treatment. Single-drug therapies with monoclonal antibodies against programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have shown little efficacy in patients with metastatic breast cancer, in part because of the low number of tumour-infiltrating lymphocytes in most breast cancers. There is growing interest in the development of combinations of immunotherapy and molecularly targeted therapies for metastatic breast cancer. In this Personal View, we review the available data and ongoing efforts to establish the safety and efficacy of immunotherapeutic approaches in combination with HER2-targeted therapy, inhibitors of cyclin-dependent kinases 4 and 6, angiogenesis inhibitors, poly(ADP-ribose) polymerase inhibitors, as well as chemotherapy and radiotherapy.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Esteva FJ, Hubbard-Lucey VM, Tang J, et al. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019. PMID: 30842061. doi:10.1016/S1470-2045(19)30026-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。